# OnCo record paper-invictus-ripretinib-lancet-oncol-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-invictus-ripretinib-lancet-oncol-2020" ;
  schema:name "INVICTUS: ripretinib in advanced gastrointestinal stromal tumours after three or more prior kinase inhibitors"@en ;
  schema:description "The switch-control KIT inhibitor ripretinib lengthened progression-free survival from one to six months and improved survival compared with placebo in gastrointestinal stromal tumours that had failed imatinib, sunitinib and regorafenib."@en ;
  schema:url <https://onco.cc/key-papers/paper-invictus-ripretinib-lancet-oncol-2020/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(20)30168-6>, <https://pubmed.ncbi.nlm.nih.gov/32511981/> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(20)30168-6> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Blay JY, Serrano C, Heinrich MC, et al." ;
  onco:cancers <https://onco.cc/cancers/gist-imatinib-resistant/> ;
  onco:drugs <https://onco.cc/drugs/ripretinib/> ;
  onco:trials <https://onco.cc/trials/invictus/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .